Cancers, Vol. 11, Pages 2003: Adjuvant Therapy for High-Risk Stage II or III Colon Adenocarcinoma: A Propensity Score-Matched, Nationwide, Population-Based Cohort Study

Conclusions: Adjuvant fluoropyrimidine alone is the most optimal regimen for patients with high-risk stage II colon adenocarcinoma compared with the other adjuvant chemotherapy regimens. Adjuvant FOLFOX can serve as an optimal regimen for patients with pathologic stage III colon adenocarcinoma, regardless of age, sex, or tumor location.

Source: Cancers - December 11, 2019 Category: Cancer & Oncology Authors: Chia-Lun Chang Kevin Sheng-Po Yuan Alexander T.H. Wu Szu-Yuan Wu Tags: Article Source Type: research